KF
Therapeutic Areas
Invivyd Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lead mAb (name not specified) | COVID-19 (Prevention/Treatment) | Approved (EUA) |
| Canopy | COVID-19 (Prevention/Treatment) | Phase 3 |
| Pipeline Candidates | Influenza and other high-need viral diseases | Pre-clinical / Research |
Leadership Team at Invivyd
RA
Robert Allen, Ph.D.
Chief Scientific Officer
JA
Jill Andersen, J.D.
Chief Legal Officer & Corporate Secretary
WD
William Duke, M.B.A.
Chief Financial Officer
RG
Rachael Gerlach, Ph.D.
Senior Vice President of Regulatory Affairs
JG
Julie Green, M.B.A.
Chief Human Resources Officer
TL
Timothy Lee
Chief Commercial Officer
MM
Michael Mina, M.D., Ph.D.
Chief Medical Officer
ME
Marc Elia
Chairman of the Board
TB
Tamsin Berry
Director
PB
Paul B. Bolno, M.D.
Director